Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Large conductance calcium-activated potassium channel subfamily M subunit alpha-1, encoded by the KCNMA1 gene and commonly known as the BK channel alpha subunit or KCa1.1, is a voltage-gated and calcium-activated potassium channel. It is uniquely activated by both membrane depolarization and increases in intracellular calcium levels, allowing potassium efflux that hyperpolarizes the cell membrane and dampens cellular excitability. This channel plays a critical role in regulating neuronal excitability, neurotransmitter release, and smooth muscle tone across various tissues.\n\nDysregulation or genetic mutations in KCNMA1 are linked to a spectrum of neurological disorders collectively termed KCNMA1-linked channelopathies, which include epilepsy, paroxysmal non-kinesigenic dyskinesia (PNKD3), ataxia, and Liang-Wang syndrome. Additionally, altered expression or epigenetic silencing of KCNMA1 is associated with cardiovascular diseases, overactive bladder, and several cancers. Pharmacologically, BK channels are targeted by channel openers like BMS-204352 (MaxiPost) to reduce excitability (e.g., for stroke or neuroprotection) and blockers like paxilline or iberiotoxin to study or modulate excitability. However, widespread tissue expression and the risk of inducing severe headaches or vascular side effects present significant therapeutic challenges.
Channel openers/activators increase potassium efflux to hyperpolarize the cell membrane and reduce excitability, whereas channel blockers/antagonists inhibit potassium efflux to prevent hyperpolarization and increase excitability or contractility.
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Large conductance calcium-activated potassium channel subfamily M subunit alpha-1 (KCNMA1).